Comparative Risk for Angioedema Associated with the Use of Drugs that Target the Renin-Angiotensin-Aldosterone System

Basic Details
Date
Monday, November 12, 2012
Type
Publication
Medical Product
aliskiren
angiotensin II receptor blocker (ARB)
angiotensin-converting enzyme (ACE) inhibitor
Health Outcome(s)
angioedema
Description

This article describes a Mini-Sentinel protocol-based one-time assessment of the risk of angioedema associated with new use of drugs that act on the renin-angiotensin-aldosterone system (RAAS), including angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and aliskiren.

Information
Time Period
2001 - 2010
Population / Cohort
All individuals 18 years of age or older
Data Source(s)
Mini-Sentinel Distributed Database (MSDD)
Author(s)

Sengwee Toh ScD; Marsha E. Reichman PhD; Monika Houstoun PharmD; Mary Ross Southworth PharmD; Xiao Ding PhD; Adrian F. Hernandez MD; Mark Levenson PhD; Lingling Li PhD; Carolyn McCloskey MD, MPH; Azadeh Shoaibi MS, MHS; Eileen Wu PharmD; Gwen Zornberg MD, MS, ScD; Sean Hennessy PharmD, PhD

Corresponding Author

S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. Email: darren_toh@harvardpilgrim.org